ClinicalTrials.gg
Drug

Sovleplenib clinical trials

Also written HMPL-523.

Includes 1 study of Sovleplenib acetate.

studies test it
15
open now
0
in phase 3
2
first study started
2014

How each study uses sovleplenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sovleplenib
3
HMPL-523 Acetate
2

Development codes

HMPL-523
13

Studies by the year they started

15 studies that test it; most in 2022 (4)

Studies that test sovleplenib, by start year
YearStudies
20141
20151
20161
20181
20192
20211
20224
20231
20241
20252

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
12
Phase 2
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 0

Hutchmed (9) · Hutchison Medipharma Limited (6)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses sovleplenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Codes

What other systems call sovleplenib · ClinicalTrials.gg INT015846

  • UNII (FDA) 9CL6353KHOSOVLEPLENIBOne source FDA
  • NCI Thesaurus C123912SovleplenibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.